Lilly Buys Prevail for $1B in Parkinson’s Push
The move follows a trend toward rare-disease treatments at big drugmakers, including AstraZeneca's deal for Alexion.
Use phrases "in quotes" or the tools below to better filter your results.
This is premium content
To read the full story, please upgrade your plan to Gold, Platinum, or Enterprise.
Upgrade plan